The First Year—Crohn's Disease and Ulcerative Colitis: An Essential Guide for the Newly Diagnosed

2002 ◽  
Vol 123 (3) ◽  
pp. 953
Author(s):  
Anthea L. Darling
Keyword(s):  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
First Year ◽  
Newly Diagnosed

TREATMENT PATTERNS OF NEWLY DIAGNOSED PEDIATRIC ULCERATIVE COLITIS AND CROHN’S DISEASE PATIENTS IN THE IMPROVECARENOW REGISTRY

2021 ◽  
Vol 27 (Supplement_1) ◽  
pp. S22-S23
Author(s):  
Theresa Hunter ◽  
Wendy Komocsar ◽  
Richard Colletti ◽  
Chunyan Liu ◽  
Keith Benkov ◽  
...  
Keyword(s):  
United States ◽  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
The United States ◽  
Current Treatment ◽  
Treatment Patterns ◽  
Initial Visit ◽  
Newly Diagnosed ◽  
Time Points

Abstract Objectives The objective of this study was to assess current treatment patterns of pediatric ulcerative colitis (UC) and Crohn’s disease (CD) patients, using data in the ImproveCareNow (ICN) registry. Methods Pediatric (2–17 years) patients in the United States who were newly diagnosed with UC or CD between June 1, 2013-December 31, 2019, who had their first recorded ICN visit within 6 months of diagnosis and who were actively followed for at least 12 months (± 90 days) were included in this study. Descriptive statistics of baseline patient demographics were summarized for the overall IBD patient population and separately for UC and CD. Treatment patterns (including use of corticosteroids, 5-aminosalicylic acid (5-ASA), 6-mercaptopurine/azathioprine (6-MP/AZA), methotrexate, tumor necrosis factor inhibitors (TNFi) [adalimumab, infliximab, certolizumab, golimumab, and their biosimilars], ustekinumab, vedolizumab, and other medications [natalizumab and tofacitinib]) were assessed at the initial baseline visit, and at 1-year and 3-year time points. Results A total of 6,504 pediatric IBD patients (UC=1,784; CD=4,720) were included in this study. Patients had a mean age at diagnosis of 13.0 years (UC=13.2; CD=12.9), 57.1% were male (UC=49.6%; CD=60.0%), and 81.0% were White (UC=81.2%; CD=81.0%) (Table 1). At the initial ICN visit, 46.4% of UC patients were prescribed a corticosteroid, while 19.8% received a 5-ASA, 12.6% received a TNFi, 10.4% received a 6-MP/AZA, 3.0% received methotrexate, and 0.3% received vedolizumab. At the initial visit, 40.2% of CD patients were prescribed a corticosteroid, while 29.1% received a TNFi, 18.5% received a 6-MP/AZA, 12.4% received methotrexate, and 3.3% received a 5-ASA. At the 1-year and 3-year time points, rates of 5-ASA and corticosteroid use decreased among UC patients; however, rates of 6-MP/AZA, methotrexate, and TNFi increased (Table 2). Similarly, at the 1-year and 3-year time points, rates of corticosteroids among CD patients decreased; however, rates of methotrexate and TNFi increased (Table 2). There was also an increase in use of ustekinumab and vedolizumab over time among UC and CD patients. Conclusion These results highlight the current treatment patterns of pediatric UC and CD patients in the United States. At the initial ICN visit, the 46% of UC and 40% of CD patients were receiving corticosteroids, however, at 1-year and 3-years after initial visit, over 30% of UC patients and over 60% of CD patients were receiving TNF inhibitors with considerably reduced corticosteroid use.

Sa1781 - Serological Markers Define Newly Diagnosed Crohn's Disease and Ulcerative Colitis Based on the age at Diagnosis

2018 ◽  
Vol 154 (6) ◽  
pp. S-392
Author(s):  
Sare Verstockt ◽  
Elien Glorieus ◽  
Muriel De Decker ◽  
Bram Verstockt ◽  
Nooshin Ardeshir Davani ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Age At Diagnosis ◽  
Serological Markers ◽  
Newly Diagnosed

scholarly journals P798 Societal costs attributable to Crohn’s disease and ulcerative colitis within the first 5 years after diagnosis: –a Danish Nationwide Cost-of-Illness Study 2003–2015

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S627-S627
Author(s):  
S ALULIS ◽  
K Vadstrup ◽  
A Borsi ◽  
S Elkjær Stallknecht ◽  
J Olsen ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
General Population ◽  
Hospital Admission ◽  
Cost Of Illness ◽  
Control Group ◽  
First Year ◽  
Production Loss ◽  
Societal Costs

Abstract Background There is little information on cost-of-illness among patients diagnosed with Crohn’s disease (CD) and ulcerative colitis (UC) in Denmark. The objective of this study was to estimate the average 5-year societal costs attributable to CD or UC including costs related to health care, prescription medicine, home care, and production loss. Methods Incident patients with CD or UC were identified in the National Patient Registry and matched with a non-IBD control from the general population on age and sex. Attributable costs were estimated applying a difference-in-difference approach, where the total costs among individuals in the control group were subtracted from the total costs among patients. Information on primary and secondary healthcare services were obtained from the National Health Insurance Service Registry. Results CD and UC incidence was approximately 14 and 31 per 100,000 persons-years, respectively. Average attributable costs were highest the first year after diagnosis, with costs equalling €12,919 per CD patient and €6,501 per UC patient. Hospital admission costs accounted for 36% in the CD population and 31% in the UC population, the first year after diagnosis. Production loss exceeded all other costs the third year after diagnosis. Conclusion We found that the societal costs attributable to incident CD and UC patients are substantial compared with the general population, primarily consisting of hospital admission costs and production loss. Appropriate treatment at the right time may be beneficial from a societal perspective.

scholarly journals P179 Treatment decisions and biologic adoption rates in newly diagnosed Crohn’s disease in Japan

2021 ◽  
Vol 15 (Supplement_1) ◽  
pp. S251-S251
Author(s):  
T Hisamatsu ◽  
A Yoon
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Real World ◽  
Biologic Therapy ◽  
Treatment Decisions ◽  
Health Claims ◽  
First Year ◽  
Newly Diagnosed ◽  
Optimal Care ◽  
Danish Study

Abstract Background Biologic therapy in Crohn’s disease (CD) has significantly improved treatment outcomes. Still, providing an optimal care for individual patient in real-world is complex. We report the real-world treatment decisions between biologics and systemic corticosteroids (SCS) and associated factors in newly diagnosed CD in Japan. Methods Patients with CD diagnosis (Index) and at least one CD therapeutic agent prescribed between 2006 and 2019 were screened from the JMDC database. JMDC is a health claims database where various sized (small to very large) companies’ employees and their dependents are enrolled. Subjects with a minimum 12-month CD-diagnosis-free enrolment period up to the Index, and a minimum 12-month observational period after the Index were included in the analysis. Subjects were categorised into 2 groups (A: without biologics, B: with biologics) based on their first-year treatment, and then further into 4 groups: SCS without biologics (A1), No SCS nor biologics (A2), Biologics with no prior SCS (B1), Biologics with prior SCS (B2). Results 859 subjects were included. 38.4% (B: n=330/859) initiated biologics within a year since diagnosis (Table 1). Among them, 73.3% (B2: n=242/330) initiated biologics without prior SCS, so-called a top-down approach. Among the rest who were not treated with biologics within the first year, 27.2% (A1: n=114/529) received SCS. B were 7.5 years younger on average and had a higher rate of perianal symptoms (43.0%) compared to A (22.9%). Trend analyses showed that the rates of biologic adoption in the first year have been relatively stable over a decade since 2008 to 2019 (Table 2). Conclusion Real-world treatment decisions in newly diagnosed CD were investigated, and perianal symptoms were strongly associated with biologic therapy. Biologic adoption rates in CD seemed higher and faster in Japan compared to Europe. According to a Danish study reported by Alulis et al. (2020), 28.5% of CD patients received biologics at some point during the whole study period, of which 46.2% received within a year. These figures suggest that 13.2% of newly diagnosed CD were treated with biologics within the first year in the Danish study compared to 38.4% in our study.

scholarly journals P117 Serum proteomic analysis characterises newly diagnosed Crohn’s disease and ulcerative colitis depending on the age at diagnosis

2018 ◽  
Vol 12 (supplement_1) ◽  
pp. S151-S152
Author(s):  
S Verstockt ◽  
E Glorieus ◽  
M De Decker ◽  
B Verstockt ◽  
N Ardeshir Davani ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Proteomic Analysis ◽  
Age At Diagnosis ◽  
Newly Diagnosed

TREATMENT PATTERNS OF NEWLY DIAGNOSED PEDIATRIC ULCERATIVE COLITIS AND CROHN’S DISEASE PATIENTS IN THE IMPROVECARENOW REGISTRY

2021 ◽  
Vol 160 (3) ◽  
pp. S29-S30
Author(s):  
Theresa Hunter ◽  
Wendy Komocsar ◽  
Richard Colletti ◽  
Chunyan Liu ◽  
Keith Benkov ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Treatment Patterns ◽  
Newly Diagnosed

Distinct Alterations in the Composition of Mucosal Innate Lymphoid Cells in Newly Diagnosed and Established Crohn’s Disease and Ulcerative Colitis

2018 ◽  
Vol 13 (1) ◽  
pp. 67-78 ◽  
Author(s):  
Marianne Forkel ◽  
Sophie van Tol ◽  
Charlotte Höög ◽  
Jakob Michaëlsson ◽  
Sven Almer ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Innate Lymphoid Cells ◽  
Lymphoid Cells ◽  
Newly Diagnosed

scholarly journals The cost burden of Crohn’s disease and ulcerative colitis depending on biologic treatment status – a Danish register-based study

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Sarah Alulis ◽  
Kasper Vadstrup ◽  
Jens Olsen ◽  
Tine Rikke Jørgensen ◽  
Niels Qvist ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Healthcare Costs ◽  
Treatment Initiation ◽  
Annual Production ◽  
First Year ◽  
Biologic Treatment ◽  
Production Values ◽  
Average Annual Production

Abstract Background Patients diagnosed with inflammatory bowel disease may be treated with biologics, depending on several medical and non-medical factors. This study investigated healthcare costs and production values of patients treated with biologics. Methods This national register study included patients diagnosed with Crohn’s disease (CD) and ulcerative colitis (UC) between 2003 and 2015, identified in the Danish National Patient Register (DNPR). Average annual healthcare costs and production values were compared for patients receiving biologic treatment or not, and for patients initiating biologic treatment within a year after diagnosis or at a later stage. Cost estimates and production values were based on charges, fees and average gross wages. Results Twenty-six point one percent CD patients and ten point seven percent of UC patients were treated with biologics at some point in the study period. Of these, 46.4 and 45.5 % of patients initiated biologic treatment within the first year after diagnosis. CD and UC patients treated with biologics had higher average annual healthcare costs after diagnosis compared to patients not treated with biologics. CD patients receiving biologics early had lower production values both ten years before and eight years after treatment initiation, compared to patients receiving treatment later. UC patients receiving biologics early had lower average annual production values the first year after treatment initiation compared to UC patients receiving treatment later. Conclusions CD and UC patients receiving biologic treatment had higher average annual healthcare costs and lower average annual production values, compared to patients not receiving biologic treatment. The main healthcare costs drivers were outpatient visit costs and admission costs.

Sign in / Sign up

Export Citation Format

Share Document